CME Group Tidigare resultatutveckling
Tidigare kriterier kontrolleras 4/6
CME Group har ökat intäkterna med en genomsnittlig årlig takt på 12.5%, medan Capital Markets -branschen såg intäkterna växer på 4.5% årligen. Intäkterna har varit växande med en genomsnittlig takt på 8.5% per år. CME Group s avkastning på eget kapital är 16% och den har en nettomarginal på 62.9%.
Viktig information
12.55%
Tillväxttakt i vinsten
12.46%
Tillväxttakt för EPS
| Capital Markets Tillväxt i branschen | 10.26% |
| Intäkternas tillväxttakt | 8.55% |
| Avkastning på eget kapital | 16.04% |
| Nettomarginal | 62.95% |
| Senaste uppdateringen av resultatet | 31 Mar 2026 |
Senaste uppdateringar av tidigare prestationer
Recent updates
CME: Volatile Street Views And New Futures Will Shape Trading Mix
Analysts have nudged their fair value estimate for CME Group down to $308.20 from $311.67, reflecting slightly softer revenue growth assumptions and a higher discount rate, partly balanced by a higher projected profit margin and a modestly lower future P/E, in line with the mix of recent price target trims and increases across the Street. Analyst Commentary Recent Street research on CME Group has been active on both sides, with several firms adjusting price targets and ratings in different directions.CME Group Q1 Earnings Show Strength, But The Stock Still Looks Expensive
Apr 23CME: Volatility And New Contracts Will Shape Rare Earths And Crypto Volumes
The updated analyst price target for CME Group has moved higher by about $5 to $311.67. This change reflects analysts' use of a slightly lower discount rate, a modestly higher assumed revenue growth rate, and a marginally higher future P/E multiple, even as they factor in a small trim to projected profit margins.CME: Volatility And New Contracts Will Shape Rare Earths And Volume Mix
Analysts have made a modest upward adjustment to the CME Group fair value estimate to about $307 from roughly $305, reflecting slightly revised assumptions for discount rate, revenue growth, profit margin, and future P/E following a mix of recent rating changes and price target tweaks across the Street. Analyst Commentary Recent research on CME Group reflects a mixed but generally balanced backdrop, with several firms adjusting ratings and price targets in different directions.CME: Volatility And New Contracts Will Shape Rare Earths And Clearing Outlook
Our analyst price target for CME Group has moved modestly higher to $305.21 from $299.29, as analysts factor in slightly stronger modeled revenue growth and profitability. This is partially offset by a more conservative future P/E assumption and mixed views on volume drivers across product lines.CME: Volatility And New Contracts Will Shape Futures And Clearing Outlook
The analyst price target for CME Group edges higher to $232, with recent updates reflecting analysts' focus on firmer commodities volumes, as well as a more expense conscious outlook in their refreshed earnings models. Analyst Commentary Recent Street research around CME Group reflects a mix of optimism on volumes and earnings power, alongside caution on valuation and the cost base.CME: Volatility And Prediction Markets Will Guide Futures And Clearing Expansion Outlook
The updated analyst price target for CME Group edges higher to about US$297 from roughly US$290, reflecting analysts' use of a slightly lower discount rate, a modestly higher assumed revenue growth rate, and a similar future P/E multiple despite a slightly lower profit margin input. Analyst Commentary Street research on CME Group in recent sessions centers on a cluster of revised price targets and at least one rating change, with several bullish analysts lifting their targets by varying dollar amounts and one major bank fine tuning its view in both directions over a short time frame.CME: Volatility And Prediction Markets Will Shape Futures Activity Outlook
The analyst price target for CME Group is now US$290.40, a move of about US$2 from the prior US$288.33, as analysts factor in slightly different assumptions for fair value, discount rate, revenue growth, profit margins, and future P/E following mixed recent research that includes both a modest target cut and an upgrade linked to a tilt toward volatility. Analyst Commentary Recent research on CME Group reflects a mix of optimism and caution, with one firm trimming its price target slightly and another upgrading the stock on what it sees as a better setup for volatility related trading activity.CME: Fee Moat And Prediction Markets Will Shape Futures Activity Outlook
Narrative Update: CME Group CME Group's fair value estimate has edged up by about $1 to roughly $288 per share, as analysts cite the company's strong futures and options moat, a higher price target range of up to $314, and interest in its role within prediction markets as key supports for the updated outlook. Analyst Commentary Recent Street research has been generally constructive on CME Group, with several bullish analysts adjusting their price targets higher and highlighting the company's futures and options franchise as a key support for valuation.CME: Fee Resilience And Prediction Markets Will Balance Lower Volatility Risks
Analysts have nudged their average price target on CME Group modestly higher, to approximately $287 from about $286, citing the company’s resilient fee-based revenue mix, strong competitive moat in futures and options, and supportive demand signals from prediction market partnerships despite some conflicting views on near term volume volatility. Analyst Commentary Recent Street research presents a mixed but generally constructive view on CME Group, with upward moves in price targets tempered by concerns around volume sensitivity and valuation risk if volatility normalizes.CME: Fee Resilience And New Prediction Markets Will Help Navigate Volatility
Analysts have raised their fair value estimate for CME Group by about $1 to roughly $286 per share, citing the company’s resilient clearing and transaction fee driven revenue base, modestly higher long term growth expectations, and a reinforced competitive moat highlighted in recent target revisions across the Street. Analyst Commentary Street research on CME Group reflects a wide range of views on valuation and execution, with recent target changes clustering around expectations for resilient fee income but diverging on the sustainability of growth and the impact of lower volatility.CME: Revenue Resilience And New Ventures Will Balance Volatility Risks Ahead
The average analyst price target for CME Group was raised by approximately $3 to $285, as analysts point to the firm's resilient revenue streams and strong market position amid continued macroeconomic uncertainty. Analyst Commentary Recent analyst activity reflects a mix of optimism and caution regarding CME Group's performance and outlook, particularly as the firm navigates shifting macroeconomic and market conditions.CME: More Market Volatility Equals More Demands - Initiating With Strong Buy
Apr 27CME Group At A New All-Time High - Valuation Concerns Justified?
Mar 27CME Group: High Quality With Good Dividend Yield
Feb 18CME Group: Exchanges And Data Will Keep Growing, And So Could Its Dividend
Dec 30CME Group's Dominance Challenged By Now Operational FMX?
Dec 13Fördelning av intäkter och kostnader
Fördelning av intäkter och kostnader
Hur CME Group tjänar och spenderar pengar. Baserat på senast rapporterade resultat, på rullande tolvmånadersbasis.
Resultat- och intäktshistorik
| Datum | Intäkter | Intäkter | G+A Kostnader | FoU-kostnader |
|---|---|---|---|---|
| 31 Mar 26 | 6,744 | 4,245 | 1,790 | 0 |
| 31 Dec 25 | 6,507 | 4,021 | 1,751 | 0 |
| 30 Sep 25 | 6,385 | 3,717 | 1,695 | 0 |
| 30 Jun 25 | 6,433 | 3,721 | 1,681 | 0 |
| 31 Mar 25 | 6,274 | 3,581 | 1,654 | 0 |
| 31 Dec 24 | 6,120 | 3,482 | 1,646 | 0 |
| 30 Sep 24 | 6,034 | 3,422 | 1,630 | 0 |
| 30 Jun 24 | 5,788 | 3,262 | 1,590 | 0 |
| 31 Mar 24 | 5,616 | 3,157 | 1,577 | 0 |
| 31 Dec 23 | 5,579 | 3,186 | 1,515 | 0 |
| 30 Sep 23 | 5,338 | 3,011 | 1,536 | 0 |
| 30 Jun 23 | 5,228 | 2,942 | 1,519 | 0 |
| 31 Mar 23 | 5,104 | 2,828 | 1,491 | 0 |
| 31 Dec 22 | 5,019 | 2,657 | 1,399 | 0 |
| 30 Sep 22 | 4,833 | 2,633 | 1,443 | 0 |
| 30 Jun 22 | 4,715 | 2,889 | 1,440 | 0 |
| 31 Mar 22 | 4,657 | 2,745 | 1,448 | 0 |
| 31 Dec 21 | 4,690 | 2,617 | 1,418 | 0 |
| 30 Sep 21 | 4,630 | 2,435 | 1,521 | 0 |
| 30 Jun 21 | 4,600 | 1,920 | 1,543 | 0 |
| 31 Mar 21 | 4,603 | 1,913 | 1,564 | 0 |
| 31 Dec 20 | 4,884 | 2,105 | 1,491 | 0 |
| 30 Sep 20 | 4,911 | 2,151 | 1,545 | 0 |
| 30 Jun 20 | 5,109 | 2,375 | 1,539 | 0 |
| 31 Mar 20 | 5,200 | 2,386 | 1,532 | 0 |
| 31 Dec 19 | 4,868 | 2,117 | 1,447 | 0 |
| 30 Sep 19 | 4,959 | 2,033 | 1,518 | 0 |
| 30 Jun 19 | 4,588 | 1,808 | 1,370 | 0 |
| 31 Mar 19 | 4,377 | 1,860 | 1,235 | 0 |
| 31 Dec 18 | 4,309 | 1,962 | 1,126 | 0 |
| 30 Sep 18 | 3,973 | 4,516 | 977 | 0 |
| 30 Jun 18 | 3,959 | 4,413 | 996 | 0 |
| 31 Mar 18 | 3,824 | 4,262 | 993 | 0 |
| 31 Dec 17 | 3,645 | 4,063 | 929 | 0 |
| 30 Sep 17 | 3,658 | 1,498 | 1,014 | 0 |
| 30 Jun 17 | 3,609 | 1,662 | 1,000 | 0 |
| 31 Mar 17 | 3,590 | 1,566 | 1,008 | 0 |
| 31 Dec 16 | 3,595 | 1,534 | 971 | 0 |
| 30 Sep 16 | 3,496 | 1,452 | 984 | 0 |
| 30 Jun 16 | 3,505 | 1,340 | 994 | 0 |
| 31 Mar 16 | 3,418 | 1,284 | 986 | 0 |
| 31 Dec 15 | 3,327 | 1,247 | 985 | 0 |
| 30 Sep 15 | 3,354 | 1,262 | 998 | 0 |
| 30 Jun 15 | 3,266 | 1,192 | 985 | 0 |
Kvalitetsintäkter: CME har inkomster av hög kvalitet.
Växande vinstmarginal: CME s nuvarande netto vinstmarginaler (62.9%) är högre än förra året (57.1%).
Fritt kassaflöde vs resultatanalys
Analys av tidigare vinsttillväxt
Resultatutveckling: CME s intäkter har ökat med 12.5% per år under de senaste 5 åren.
Accelererande tillväxt: CME s intäktstillväxt under det senaste året ( 18.5% ) överstiger sitt 5-åriga genomsnitt ( 12.5% per år).
Resultat vs industri: CME vinsttillväxt under det senaste året ( 18.5% ) överträffade inte Capital Markets branschen 20.1%.
Avkastning på eget kapital
Hög ROE: CME s avkastning på eget kapital ( 16% ) anses vara låg.
Avkastning på tillgångar
Avkastning på sysselsatt kapital
Upptäck starka bolag som tidigare presterat bra
Företagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/04/30 19:51 |
| Aktiekurs vid dagens slut | 2026/04/29 00:00 |
| Intäkter | 2026/03/31 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
CME Group Inc. bevakas av 34 analytiker. 13 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Stephen Biggar | Argus Research Company |
| Benjamin Budish | Barclays |
| Roger Freeman | Barclays |